<div id="readability-page-1"><div><p>Inventiva (ENXTPA:IVA) reshaped its leadership team, appointing a new Chief Financial Officer, Chief Legal Officer, and Chief People Officer as it prepares for a key Phase 3 NATiV3 data readout later this year.</p> <p>See our latest analysis for Inventiva.</p> <p>The latest leadership reshuffle comes as the share price sits at €4.31, with a 6.55% year to date share price return but a 16.15% decline over 90 days. At the same time, the 1 year total shareholder return of 33.02% and 3 year total shareholder return of 79.58% suggest longer term holders have seen stronger momentum.</p> <p>If you are weighing Inventiva’s setup against other opportunities in the market, this is a good moment to widen the lens and check out 125 healthcare AI stocks</p> <p>With revenue of €6.761m against a net loss of €354.138m and the share price well below the €10.0004 analyst target, investors have to ask: is risk already reflected, or is the market quietly pricing in future growth?</p> <h2>Most Popular Narrative: 56.9% Undervalued</h2> <p>With the most followed fair value sitting at €10.00 against a last close of €4.31, the current market price sits well below that narrative anchor.</p> <blockquote> <p><em>Strong financial backing from dilutive and nondilutive financing operations, including a structured deal worth up to €348 million, ensures a cash runway sufficient to reach September 2026 with the second tranche. This financial strength can support sustained investment in commercialization, potentially affecting future earnings.</em></p> </blockquote> <p>Read the complete narrative.</p> <p>Curious how that runway, the revenue ramp assumptions and future margin profile all connect to a single fair value number? The full narrative lays out the growth curve, embedded profitability swing and the earnings multiple used to arrive at that €10 mark, as well as how analyst disagreements shape the range around it.</p> <p><strong>Result: Fair Value of €10.00 (UNDERVALUED)</strong></p> <p>Have a read of the narrative in full and understand what's behind the forecasts.</p> <p>However, the thesis still leans heavily on lanifibranor and sits against a backdrop of sizeable losses and auditor flagged going concern risk, which could challenge that €10 narrative.</p> <p>Find out about the key risks to this Inventiva narrative.</p> <h2>Next Steps</h2> <p>With sentiment clearly split between concern over losses and optimism around potential rewards, it helps to look at the numbers yourself and decide quickly where you stand. Start with the 1 key reward and 4 important warning signs.</p> <h2>Looking for more investment ideas?</h2> <p>If Inventiva is on your radar, do not stop there. Widen your opportunity set with fresh stock ideas filtered by quality, value and risk.</p> <ul> <li>Target cash generative businesses by scanning the solid balance sheet and fundamentals stocks screener (385 results) and see which companies pair financial strength with ongoing operations.</li> <li>Hunt for potential value opportunities using the 245 high quality undervalued stocks to surface companies where the current price sits below fundamental estimates.</li> <li>Prioritise resilience and steadier profiles through the 304 resilient stocks with low risk scores and focus on businesses with lower overall risk scores.</li> </ul> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data     and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your     financial situation. We aim to bring you long-term focused analysis driven by fundamental data.     Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.     Simply Wall St has no position in any stocks mentioned.</em></p><div><h3><strong>New: </strong>AI Stock Screener &amp; Alerts</h3><p>Our new AI Stock Screener scans the market every day to uncover opportunities.</p><div><p>• Dividend Powerhouses (3%+ Yield)<br/>• Undervalued Small Caps with Insider Buying<br/>• High growth Tech and AI Companies</p><p>Or build your own from over 50 metrics.</p></div><p>Explore Now for Free</p></div></div></div>

ARKG

LABU

<p>Inventiva (ENXTPA:IVA) has appointed a new leadership team as it prepares for a key Phase 3 data readout. The share price is currently €4.31, reflecting a 6.55% year-to-date return but a 16.15% decline over the past 90 days. Despite a net loss of €354.138 million, the company has strong financial backing, ensuring a cash runway until September 2026. Analysts suggest a fair value of €10.00, indicating the stock is undervalued. However, concerns over losses and auditor flagged risks may challenge this narrative.</p>

Simplywall

Inventiva SA

Invesco Biotechnology & Genome ETF

First Trust NYSE Arca Biotech Index Fd

VanEck Biotech ETF

iShares Biotechnology ETF

SPDR S&P Biotech

Ark Genomic Revolution ETF

Proshares Ultra Nasdaq Biotech

Direxion S&P Biotech Bull 3X

A Look At Inventiva (ENXTPA:IVA) Valuation As New Leadership Team Prepares For Key Phase 3 Readout